Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a randomized controlled trial.

SS analogs are an attractive alternative in treating Graves' ophthalmopathy (GO).

Most of the previous studies were uncontrolled and enrolled few patients.

Who Took Part

The study group was 14 patients.

PubMed indexes the participants as teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Somatostatin group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Somatostatin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Somatostatin group a baseline to be compared against.

A time span of 12 weeks appears in the methods.

What Was Measured

Proptosis, diplopia, corneal erosion or ulcer, visual acuity, extraocular muscle movement and intraocular pressure were also evaluated.

PubMed files the paper under topics including Graves Ophthalmopathy, Peptides, Cyclic and Somatostatin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Somatostatin and Lanreotide in 14 patients over 12 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2006 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.